Mirae Asset Global Investments Co., Ltd. Tg Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$13.02 - $21.3 $86,491 - $141,495	-6,643 Reduced 8.18%	74,538 $1.13 Million
Q4 2023 Jan 24, 2024	SELL	$6.68 - $18.81 $29,385 - $82,745	-4,399 Reduced 5.14%	81,181 $1.39 Million
Q3 2023 Oct 26, 2023	BUY	$8.36 - $26.5 $143,850 - $455,985	17,207 Added 25.17%	85,580 $715,000
Q2 2023 Aug 10, 2023	SELL	$15.48 - $35.0 $123,174 - $278,495	-7,957 Reduced 10.42%	68,373 $1.7 Million
Q1 2023 May 04, 2023	BUY	$10.23 - $19.34 $187,249 - $353,999	18,304 Added 31.54%	76,330 $1.15 Million
Q4 2022 Feb 09, 2023	BUY	$5.01 - $11.83 $20,535 - $48,491	4,099 Added 7.6%	58,026 $686,000
Q3 2022 Nov 10, 2022	BUY	$4.57 - $8.4 $77,690 - $142,800	17,000 Added 46.04%	53,927 $319,000
Q2 2022 Jul 26, 2022	BUY	$3.74 - $10.66 $138,106 - $393,641	36,927 New	36,927 $157,000

287

91.8M

1.9M

1.45M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.12B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.